Hospital
Pennock Hospital
Pennock Hospital was paid $15.24M by Medicaid between Feb 2019 and Dec 2024, across 210 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoPENNOCK HOSPITAL
HASTINGS, MI 49058
HASTINGS, MI 49058
33aNPI1932695525assigned 07/06/2018
33bProvider typeCritical Access Hospital
28Total paid$15.24M
24GClaims444,497
24DCodes billed210
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#2 of 31
Median peer was paid$6.03M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 41,519 | $1.03M | |
| 2020 | 57,279 | $1.93M | |
| 2021 | 86,784 | $3.01M | |
| 2022 | 90,192 | $3.24M | |
| 2023 | 95,280 | $3.36M | |
| 2024incomplete | 73,443 | $2.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,198 | 9,646 | $2.70M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 14% | 26,306 | 23,684 | $2.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 5,140 | 4,820 | $2.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 9,847 | 9,303 | $1.69M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.6% | 6,688 | 5,933 | $859K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 2,612 | 2,549 | $530K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 13,496 | 4,101 | $454K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 6,238 | 6,032 | $417K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 3,092 | 2,958 | $305K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,102 | 1,896 | $254K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 4,761 | 4,596 | $248K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 1,894 | 1,859 | $204K |
198 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 4,557 | $171K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 341 | $153K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,743 | $147K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,008 | $134K |
| 80061 | Lipid panel | <1% | 7,887 | $107K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,477 | $97K |
| 86900 | <1% | 1,709 | $95K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,185 | $93K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,598 | $90K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,095 | $90K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,476 | $87K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,414 | $85K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,306 | $83K |
| 80053 | Comprehensive metabolic panel | <1% | 23,668 | $83K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 2,304 | $80K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,294 | $78K |
| 76830 | Ultrasound, transvaginal | <1% | 941 | $75K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,434 | $71K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,260 | $69K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 96 | $65K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,125 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,798 | $63K |
| 97161 | <1% | 900 | $58K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 720 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,484 | $43K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 535 | $42K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 181 | $42K |
| 80050 | General health panel | <1% | 1,470 | $41K |
| 82947 | <1% | 2,599 | $41K | |
| 87428 | <1% | 1,422 | $38K | |
| 71045 | Radiologic examination, chest; single view | <1% | 704 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,094 | $37K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 408 | $34K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 583 | $33K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 420 | $32K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,774 | $32K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,897 | $29K |
| G0378 | Hospital observation service, per hour | <1% | 170 | $23K |
| 97162 | <1% | 381 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,694 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,488 | $22K |
| 73630 | <1% | 1,506 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 136 | $21K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 853 | $21K |
| 85027 | <1% | 6,669 | $21K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,019 | $20K |
| 73562 | <1% | 880 | $18K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 1,282 | $18K |
| 82728 | <1% | 1,960 | $18K | |
| 82607 | <1% | 1,793 | $16K | |
| 72100 | <1% | 337 | $16K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 63 | $15K |
| 84702 | <1% | 1,875 | $15K | |
| 86780 | <1% | 1,476 | $14K | |
| 73130 | <1% | 1,189 | $14K | |
| 73610 | <1% | 1,165 | $14K | |
| 93975 | <1% | 80 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,923 | $13K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 116 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,100 | $12K |
| 87653 | <1% | 492 | $11K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 405 | $11K |
| 73030 | <1% | 576 | $11K | |
| 74018 | <1% | 295 | $10K | |
| 73110 | <1% | 668 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,742 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 96 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 574 | $10K |
| 87077 | <1% | 2,965 | $9K | |
| 83550 | <1% | 1,521 | $9K | |
| C9399 | Unclassified drugs or biologicals | <1% | 157 | $9K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $9K |
| 84439 | <1% | 1,560 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 52 | $8K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 436 | $8K |
| 87186 | <1% | 2,184 | $7K | |
| 81001 | <1% | 11,724 | $7K | |
| 83540 | <1% | 1,562 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 705 | $6K |
| 82570 | <1% | 1,911 | $6K | |
| 87081 | <1% | 4,126 | $6K | |
| 85610 | <1% | 2,901 | $5K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 387 | $5K |
| 84146 | <1% | 403 | $5K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 155 | $5K |
| 83735 | <1% | 2,670 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 484 | $5K |
| 93971 | <1% | 63 | $4K | |
| 87205 | <1% | 2,623 | $4K | |
| 83880 | <1% | 644 | $4K | |
| 82043 | <1% | 1,101 | $4K | |
| 86140 | <1% | 2,087 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $4K |
| 83655 | <1% | 393 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| 72141 | <1% | 14 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 91 | $3K |
| 0012A | <1% | 85 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 249 | $3K |
| 82746 | <1% | 266 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $3K |
| 82950 | <1% | 703 | $2K | |
| 80076 | <1% | 401 | $2K | |
| 87340 | <1% | 1,171 | $2K | |
| 76801 | <1% | 26 | $2K | |
| 0011A | <1% | 97 | $2K | |
| 85652 | <1% | 1,504 | $2K | |
| 96376 | <1% | 1,040 | $2K | |
| 87070 | <1% | 607 | $2K | |
| 0002A | <1% | 51 | $2K | |
| 76536 | <1% | 26 | $2K | |
| 0001A | <1% | 56 | $2K | |
| 73502 | <1% | 62 | $2K | |
| 76642 | <1% | 26 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,774 | $1K |
| 83690 | <1% | 3,887 | $1K | |
| 73140 | <1% | 112 | $1K | |
| 82565 | <1% | 1,221 | $1K | |
| 85007 | <1% | 857 | $1K | |
| 87147 | <1% | 740 | $1K | |
| 71250 | <1% | 14 | $1K | |
| 87563 | <1% | 56 | $1K | |
| 84100 | <1% | 946 | $1K | |
| 81025 | <1% | 6,045 | $1K | |
| 97022 | <1% | 152 | $994.45 | |
| 85730 | <1% | 1,100 | $928.53 | |
| 80074 | <1% | 25 | $877.80 | |
| 86850 | <1% | 1,603 | $812.67 | |
| 86480 | <1% | 24 | $788.56 | |
| 84156 | <1% | 438 | $698.75 | |
| 84403 | <1% | 36 | $661.38 | |
| 86038 | <1% | 70 | $603.80 | |
| 86762 | <1% | 772 | $599.52 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,032 | $496.13 |
| 84481 | <1% | 40 | $441.74 | |
| 73080 | <1% | 46 | $433.18 | |
| 82784 | <1% | 41 | $298.08 | |
| 83516 | <1% | 27 | $271.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 467 | $269.62 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $258.64 |
| 73090 | <1% | 27 | $250.58 | |
| 85379 | <1% | 348 | $228.15 | |
| 81002 | <1% | 2,405 | $198.94 | |
| 84425 | <1% | 13 | $189.40 | |
| 86787 | <1% | 230 | $179.30 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 73 | $169.78 |
| 87807 | <1% | 462 | $140.00 | |
| 83605 | <1% | 3,157 | $116.87 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,744 | $108.06 |
| 84484 | <1% | 3,316 | $105.34 | |
| 85018 | <1% | 108 | $102.66 | |
| 86431 | <1% | 25 | $100.64 | |
| 86308 | <1% | 57 | $91.00 | |
| 88304 | <1% | 12 | $80.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,822 | $64.32 |
| 82248 | <1% | 15 | $53.06 | |
| 82077 | <1% | 585 | $47.33 | |
| 87040 | <1% | 120 | $43.76 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,294 | $33.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,158 | $21.58 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,946 | $21.22 |
| 80143 | <1% | 220 | $14.99 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,654 | $10.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,766 | $1.91 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 573 | $1.27 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,472 | $0.98 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,810 | $0.05 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,644 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 396 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 896 | $0.00 |
| 80179 | 0% | 218 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 207 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 374 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 6,457 | $0.00 |
| 90715 | 0% | 170 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 40 | $0.00 |
| 91300 | 0% | 115 | $0.00 | |
| 84145 | 0% | 12 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,036 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 138 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,010 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,265 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 898 | $0.00 |
| 91301 | 0% | 191 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 71 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 588 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 201 | $0.00 |
| A9270 | Non-covered item or service | 0% | 413 | $0.00 |
| 12001 | 0% | 100 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 31 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 184 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 87 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 47 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 63 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 12 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 33 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.